Search Results

TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy in patients with liver cirrhosis.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.

TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses, announced today that it has entered into a research collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.

TenNor Therapeutics reported positive top-line results for TNP-2092 powder for injection from a phase II clinical trial conducted in the United States.

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.